[go: up one dir, main page]

NO992769L - Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon - Google Patents

Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon

Info

Publication number
NO992769L
NO992769L NO992769A NO992769A NO992769L NO 992769 L NO992769 L NO 992769L NO 992769 A NO992769 A NO 992769A NO 992769 A NO992769 A NO 992769A NO 992769 L NO992769 L NO 992769L
Authority
NO
Norway
Prior art keywords
prevention
procedure
treatment
heart failure
ventricular dilatation
Prior art date
Application number
NO992769A
Other languages
English (en)
Other versions
NO992769D0 (no
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO992769D0 publication Critical patent/NO992769D0/no
Publication of NO992769L publication Critical patent/NO992769L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • External Artificial Organs (AREA)
  • Electrotherapy Devices (AREA)
NO992769A 1996-12-09 1999-06-08 Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon NO992769L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3263196P 1996-12-09 1996-12-09
PCT/US1997/021934 WO1998025597A2 (en) 1996-12-09 1997-12-02 Method for treating and preventing heart failure and ventricular dilatation

Publications (2)

Publication Number Publication Date
NO992769D0 NO992769D0 (no) 1999-06-08
NO992769L true NO992769L (no) 1999-08-09

Family

ID=21865971

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992769A NO992769L (no) 1996-12-09 1999-06-08 Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon

Country Status (13)

Country Link
US (1) US5948780A (no)
EP (1) EP1028716A1 (no)
JP (1) JP2001526631A (no)
KR (1) KR20000057444A (no)
AU (1) AU741768B2 (no)
BR (1) BR9714385A (no)
CA (1) CA2263886A1 (no)
IL (1) IL128545A0 (no)
MX (1) MXPA99001974A (no)
NO (1) NO992769L (no)
NZ (1) NZ334897A (no)
WO (1) WO1998025597A2 (no)
ZA (1) ZA9711004B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9902083A3 (en) * 1995-11-17 2000-06-28 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
BR9612188A (pt) * 1995-12-22 1999-07-13 Warner Lambert Co Cetoácidos aromáticos e seus derivados como inibidores de metaloproteinases de matriz
EP0950656B1 (en) * 1996-01-23 2007-04-11 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US6624177B1 (en) * 1996-09-04 2003-09-23 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
WO2000015213A1 (en) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
ATE280164T1 (de) * 2001-02-14 2004-11-15 Warner Lambert Co Benzothiadiazine als matrix metallproteinase inhibitoren
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
MXPA03004920A (es) * 2001-02-14 2003-09-05 Warner Lambert Co Pirimidinas inhibidoras de metaloproteinasas de matriz.
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
IL159320A0 (en) * 2001-06-12 2004-06-01 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
US20030139332A1 (en) * 2001-07-09 2003-07-24 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
CA2457033A1 (en) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. A medecine for cardiac failure
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
JP2006503812A (ja) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−２阻害薬との組み合わせ
AU2003281168A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
CA2489722A1 (en) * 2002-07-17 2004-01-22 William Howard Roark Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
EP1531904A1 (en) * 2002-07-17 2005-05-25 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) 2011-08-30 2018-08-29 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN103827095A (zh) 2011-08-30 2014-05-28 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
GB201312311D0 (en) 2013-07-09 2013-08-21 Uni I Oslo Uses of enzyme inhibitors
PE20170770A1 (es) 2014-07-17 2017-07-04 Chdi Foundation Inc Metodos y composiciones para tratar trastornos relacionados con vih
DE102022132156A1 (de) * 2022-12-05 2024-06-06 Rheinisch-Westfälische Technische Hochschule Aachen, Körperschaft des öffentlichen Rechts ADAMTS12 als Zielmolekül zur Behandlung chronischer Niereninsuffizienz und Nierenfibrose

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
WO1995029689A1 (en) * 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
JPH11504646A (ja) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
AU717570B2 (en) * 1995-06-02 2000-03-30 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
HUP9902083A3 (en) * 1995-11-17 2000-06-28 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
EP0950656B1 (en) * 1996-01-23 2007-04-11 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
EP0931045A1 (en) * 1996-09-04 1999-07-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
AU4159197A (en) * 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
WO1998025597A3 (en) 2000-10-12
IL128545A0 (en) 2000-01-31
NZ334897A (en) 2001-02-23
AU741768B2 (en) 2001-12-06
CA2263886A1 (en) 1998-06-18
WO1998025597A2 (en) 1998-06-18
JP2001526631A (ja) 2001-12-18
KR20000057444A (ko) 2000-09-15
AU5590698A (en) 1998-07-03
EP1028716A1 (en) 2000-08-23
NO992769D0 (no) 1999-06-08
BR9714385A (pt) 2000-05-16
MXPA99001974A (es) 2002-03-27
US5948780A (en) 1999-09-07
ZA9711004B (en) 1998-10-05

Similar Documents

Publication Publication Date Title
NO992769L (no) Fremgangsmåte for behandling og forhindring av hjertesvikt og ventrikulaer dilatasjon
NO992641D0 (no) Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer
DE69823459D1 (de) Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
NO991381D0 (no) Kombinasjonsterapi for behandling av psykoser
NO20004098L (no) FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
FI973255A7 (fi) Karbatsoliyhdisteiden käyttö verentungosta aiheuttavan sydämen toiminnanvajauksen hoidossa
EP0738172A4 (en) EAR AND VENTRICULAR DEFIBRILLATION CATHETER
NO923130D0 (no) Behandling av kongestiv hjertesvikt
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
ZA978450B (en) Medical treatment
NO985484L (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
NO990722D0 (no) FremgangsmÕte for behandling av hjertesvikt
NO983512D0 (no) Midler for behandling og forhindring av AIDS
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
AU7854094A (en) Use of amiodarone for the treatment of heart failure
NO934311L (no) alfa,omega-diarylalkanderivater, deres fremstilling og anvendelse ved behandling av sirkulasjonssykdommer og psykoser
BR9709546A (pt) Formulação e método para tratamento de insuficiéncia cardíaca digestiva
NO20002481D0 (no) Kombinasjonsterapi for behandling av AIDS
NO995538D0 (no) Anvendelse av hepariner med lav molekylvekt for prevensjon og terapi av sentralnervesystem-trauma
FI970484A0 (fi) Menetelmä heran käsittelemiseksi
NO964291D0 (no) Fremgangsmåte for behandling av allergisk rinitt
NO984190D0 (no) Fremgangsmåte for behandling av insomnia
UA25399A (uk) Спосіб лікуваhhя хворих гломерулоhефритом

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application